-
Heavy duty contrast agent!
Time of Update: 2022-04-22
Bayer gadobutrol global sales (million euros) Source: Sales Database of Multinational Listed Companies on Minet.
Bayer gadobutrol global sales (million euros) Source: Sales Database of Multinational Listed Companies on Minet.
hospital hospital hospital Bayer gadobutrol global sales (million euros) Source: Sales Database of Multinational Listed Companies on Minet.
-
Qilu Pharmaceutical Oseltamivir Phosphate Capsules Entered the Administrative Approval Stage
Time of Update: 2022-04-22
Data source: Minet database, NMPA Recently, Qilu Pharmaceutical has entered the administrative approval stage for the production of generic oseltamivir phosphate capsules of Category 4, and is expected to be approved for marketing in the near future .
-
Read the article: The application of artificial intelligence in drug research and development
Time of Update: 2022-04-21
Artificial intelligence can increase the likelihood of successful drug development in many ways, including new target identification, drug candidate selection, prediction of chemical and physical properties of compounds, and prediction of protein structures .
-
Keji Pharmaceutical's CT041 completes the first patient enrollment in China's confirmatory phase II clinical trial
Time of Update: 2022-04-21
CT041 is also the world's first solid tumor CAR-T product selected for the PRIME program; in 2022, CT041 was granted "Regenerative Medicine Advanced Therapy" (RMAT) qualification by the US FDA for the treatment of CLDN18.
-
Immediate release or slow release?
Time of Update: 2022-04-21
The therapeutic advantages of properly designed modified release formulations include: Improve drug efficacy and reduce toxic and side effects; Ease of use, improve patient compliance; Optimize performance; Screen new active drugs or develop new clinical indications .
-
Ascletis will report the latest preclinical research results of two new anti-cancer drugs, ASC61 and ASC60, at this year's annual meeting of the American Association for Cancer Research
Time of Update: 2022-04-20
The abstract information of the poster presentations selected for the 2022 AACR annual meeting is as follows: (1) ASC61 Abstract title: In vivo efficacy evaluation of the oral PD-L1 inhibitor ASC61 in two tumor mouse models Report format: Poster presentation abstract number: 5529 Conference Category: Immunization Conference Theme: Preclinical Research on Immunotherapy Time: April 8, 2022, 12:00-1:00 pm CST Speaker/Author: Wu Jinzi, He Hanli, Ascletis Biotechnology (Hangzhou) Co.
-
CAN106 injection completed the first patient with PNH in Phase Ib/I I clinical trial in China
Time of Update: 2022-04-20
This study is a multicenter, open-label, continuous-dose Phase Ib/I I clinical trial evaluating CAN106 injection in subjects with paroxysmal nocturnal hemoglobinuria (PNH) who have not received complement inhibitor therapy previously.
Previously, Beihai Kangcheng and Beijing Union Medical College Hospital has also reached a cooperation intention on rare disease research .
-
Significantly reduces expression of pathogenic protein Novartis SMA treatment effective in Huntington's disease
Time of Update: 2022-04-20
The regulation of huntingtin gene splicing by Branaplam drug reduces the expression of huntingtin gene and mutant proteins by splicing an exon that marks RNA degradation .
-
Recent advances, applications and challenges in proteomics
Time of Update: 2022-04-20
However, despite the current limitations, leading experts are confident in the future of the field, and Mann pointed out that mass spectrometry detection technology will continue to develop in clinical applications due to its inherent specificity .
-
The TOP list of R&D investment is released!
Time of Update: 2022-04-20
Merck expects the drug's sales this year to be between $5 billion and $6 billion, which is about the Half of the company's R&D investment in 2021 .
-
Children's use of children's medicine, consideration of children's medicine research and development
Time of Update: 2022-04-20
Medicine is a magic weapon for saving people, but if it is not used properly, it can cause great harm . "It is a drug that is three-point poisonous". For adults, improper use of drugs may cause ha
-
The Italian pharmaceutical company disbanded its sales team in China and entered the Chinese market less than two years ago
Time of Update: 2022-04-15
[Pharmaceutical Network Enterprise News] In recent years, under the influence of a series of new medical reform policies such as domestic medical insurance and centralized procurement, a large number of domestic and foreign pharmaceutical companies have had to adjust their business, and at the same time abolish or adjust related sales teams .
-
Within a week, the pharmaceutical company declared 2 first generic drugs
Time of Update: 2022-04-15
Recently, the CDE website shows that Qilu Pharmaceutical's riociguat tablet (riociguat) marketing application has been accepted, which is the first riociguat generic drug to be declared for listing in China .
-
BeiGene adds 5 more innovative anti-tumor products to seize the "broad market"
Time of Update: 2022-04-15
[Pharmaceutical Network Enterprise News] On March 16, BeiGene announced that it has completed the license introduction transaction for five Novartis anti-tumor products, namely dabrafenib, trametinib, pazopanib, Everolimus and Ceritinib have both been approved and included in the National Medical Insurance Drug List .
-
11.2 billion yuan!
Time of Update: 2022-04-15
Yunnan Baiyao's overweight in the field of pharmaceutical distribution is a manifestation of the upstream and downstream cooperation of the enterprise in the industrial chain .
-
China's good milk powder should be guarded by us together!
Time of Update: 2022-04-15
The production level of domestic dairy enterprises has reached the international level, and many of them have imported high-end production equipment from abroad, but they have not paid enough attention to equipment installation and connection, and still use manual welding .
-
Feichuang Company: Expanding sales channels around market demand
Time of Update: 2022-04-15
Ye Yinguo said that with the intensification of market competition, the pharmaceutical supporting equipment industry can no longer be satisfied with making a single machine well, but must carry out multi-faceted design according to the needs of pharmaceutical companies to provide customers with integrated solutions .
-
Huadong Medicine has continued to deploy in the field of oncology, and has reached cooperation with two foreign pharmaceutical companies in February
Time of Update: 2022-04-15
According to the data, Heidelberg Pharma (formerly WILEX AG), founded in 1997, is a global biopharmaceutical company focusing on the research and development of oncology ADC drugs .
According to the cooperation agreement, Zhongmei Huadong also has the right of first negotiation (ROFN) for two other follow-up products under development of Heidelberg Pharma .
-
Help fight the epidemic!
Time of Update: 2022-04-15
A batch of 11 units used The high-speed vertical refrigerated centrifuge for the production of nucleic acid kits was delivered on the evening of the 27th, and it has reached a seamless connection with the supporting suppliers of anti-epidemic instruments .
-
[Live] In "Extraordinary Times", how can manufacturing companies free their hands and improve their safety management level?
Time of Update: 2022-04-15
In order to help safety and ensure production, at 14:00 on April 7, 2022, Beijing Carnival Industry will bring the theme "Manufacturing in "Extraordinary Times", full-stack AR head-mounted computer remote collaboration solution to help enterprises in normal production and operation" The wonderful live broadcast will help enterprises to free their hands and improve the level of safety management.
